

ESMO Asia 2019 Industry Satellite Symposium

Friday, 22 November | 12:45-14:15

Hall 405 | Level 4

Suntec Singapore Convention
& Exhibition Centre



Changing the Course for the Lung Cancer Patient: **A New Direction**

Don't miss our interactive panel discussion!

FACULTY PRESENTERS



Mei-Kim Ang, MD

National Cancer Centre Singapore
Singapore



Myung-Ju Ahn, MD

Samsung Medical Center
South Korea



Niels Reinmuth, MD, PhD

Asklepios Fachkliniken München-Gauting
Germany



Meeting Objectives

- To facilitate discussions with a global multidisciplinary audience on the following:
 - Management of unresectable Stage III non-small cell lung cancer (NSCLC) and integration of IO (immunotherapy) into standard of care, with the goal of optimizing patient treatment outcomes
 - Use of IO in first-line extensive stage small cell lung cancer (ES-SCLC), including a discussion of recently released data in this setting



Agenda

- 12:45-12:50** Opening Remarks
- 12:50-13:35** Charting the Course for the Stage III NSCLC Patient
- 13:35-14:10** Navigating the Waters of ES-SCLC
- 14:10-14:15** Closing Remarks

*This is a scientific exchange event provided
by AstraZeneca Pharmaceuticals.*

AstraZeneca 